COMPANY

Ray Therapeutics

HQ: San Francisco, CA source · raytherapeutics.com ↗

Location: San Francisco, CA · source · May 26, 2023

Profile checked Oct 10, 2026

Keywords: Stargardt Disease Retinitis Pigmentosa Stargardt Macular Dystrophy Geographic Atrophy From Age-related Macular Degeneration Retinal Dystrophies Choroideremia X-linked Retinoschisis X-lined Retinoschisis RTx-021 RTx-015

4Trials (company is sponsor)

Timeline

Feb 19, 2026 Trial start —: Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal Disease (DEFINE-IRD) source ↗
Jan 28, 2026 Trial start 1: Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-021 in Patients With Stargardt Disease source ↗
Aug 27, 2024 Trial start Phase 1: Study to Evaluate Safety of RTx-015 Injection in Retinitis Pigmentosa or Choroideremia Patients (ENVISION) source ↗
Apr 5, 2024 Trial start —: Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration source ↗

Upcoming milestones

2027-02 (ESTIMATED) · · Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal Disease (DEFINE-IRD) · NCT07502664
2030-10 (ESTIMATED) · Phase 1 · Study to Evaluate Safety of RTx-015 Injection in Retinitis Pigmentosa or Choroideremia Patients (ENVISION) · NCT06460844
Dec 1, 2030 (ESTIMATED) · 1 · Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-021 in Patients With Stargardt Disease · NCT07439887

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 4

Record	Title	Phase	Status	Start	Primary completion
NCT07439887	Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-021 in Patients With Stargardt Disease	1	Recruiting	Jan 28, 2026	Dec 1, 2030 (estimated)
NCT07502664	Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal Disease (DEFINE-IRD)	Not listed	Recruiting	Feb 19, 2026	2027-02 (estimated)
NCT06460844	Study to Evaluate Safety of RTx-015 Injection in Retinitis Pigmentosa or Choroideremia Patients (ENVISION)	Phase 1	Active, not recruiting	Aug 27, 2024	2030-10 (estimated)
NCT06375239	Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration	Not listed	Recruiting	Apr 5, 2024	Apr 30, 2026 (estimated)